Genmab A/S ADS (GMAB) Stock Price

GMABStock

$33.23+36.67%52W

Market Cap$20.42B

P/E19.49x

PEG Ratio6.02

Div yield—

Beta0.67

GMAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)8.42%

Price vs S&P 500 (4W)15.25%

PEG Ratio6.02

VGM Score58.17

P/E Ratio (Annual)19.49x

P/CF (Annual)15.83x

Book Value / Share (Quarterly)$96.96

P/TBV (Annual)4.49x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)21.97%

Cash Flow / Share (Quarterly)$14.13

Price vs S&P 500 (YTD)-6.25%

Gross Margin (TTM)93.03%

Net Profit Margin (TTM)19.08%

EPS (TTM)$12.69

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$12.69

Revenue Growth (5Y)19.19%

EPS (Annual)$15.36

ROI (Annual)8.54%

Gross Margin (Annual)93.60%

Net Profit Margin (5Y Avg)32.29%

Cash / Share (Quarterly)$24.46

P/E Basic Excl Extra (TTM)23.82x

Revenue Growth QoQ (YoY)24.86%

EPS Growth (5Y)6.82%

P/E Normalized (Annual)19.49x

ROA (Last FY)7.48%

Revenue Growth TTM (YoY)22.33%

EBITD / Share (TTM)$17.93

ROE (5Y Avg)17.15%

Operating Margin (TTM)25.95%

Cash Flow / Share (Annual)$18.35

P/B Ratio3.15x

P/B Ratio (Quarterly)2.90x

Net Income / Employee (Annual)$317,900

EV / Revenue (TTM)5.46x

Net Interest Coverage (TTM)15.44x

ROA (TTM)7.04%

EPS Growth QoQ (YoY)-9.41%

EV / EBITDA (TTM)20.05x

EPS Incl Extra (Annual)$15.36

Current Ratio (Annual)2.02x

Quick Ratio (Quarterly)2.37x

3-Month Avg Trading Volume0.14M

52-Week Price Return36.67%

EV / Free Cash Flow (Annual)19.93x

P/E Incl Extra (TTM)23.82x

Revenue / Employee (TTM)$1,363,800

Tangible BV / Share (Quarterly)$65.02

P/S Ratio (Annual)5.05x

Asset Turnover (Annual)0.29x

52-Week High$2257.00

Operating Margin (5Y Avg)34.07%

EPS Excl Extra (Annual)$15.36

CapEx CAGR (5Y)3.22%

Tangible BV CAGR (5Y)10.66%

26-Week Price Return20.35%

Quick Ratio (Annual)2.01x

13-Week Price Return26.53%

Total Debt / Equity (Annual)0.93x

Current Ratio (Quarterly)2.46x

Enterprise Value$22.54B

Revenue / Share Growth (5Y)20.38%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)14.61%

Revenue / Employee (Annual)$1,228,100

Inventory Turnover (Annual)17.89x

Pretax Margin (Annual)32.37%

Cash / Share (Annual)$27.83

3-Month Return Std Dev34.98%

Gross Margin (5Y Avg)97.53%

Net Income / Employee (TTM)$260,200

EBITDA CAGR (5Y)2.32%

EBITDA Interim CAGR (5Y)24.81%

ROE (Last FY)16.47%

Net Interest Coverage (Annual)2.98x

EPS Basic Excl Extra (Annual)$15.36

P/FCF (TTM)21.58x

Receivables Turnover (TTM)3.97x

EV / Free Cash Flow (TTM)25.97x

Total Debt / Equity (Quarterly)0.89x

EPS Incl Extra (TTM)$12.69

Receivables Turnover (Annual)3.67x

ROI (TTM)7.99%

P/S Ratio (TTM)4.54x

Pretax Margin (5Y Avg)40.72%

Revenue / Share (Annual)$59.34

Tangible BV / Share (Annual)$53.22

Forward P/E19.02x

Free OCF CAGR (5Y)3.84%

Price vs S&P 500 (52W)18.11%

P/E Ratio (TTM)23.82x

EPS Growth TTM (YoY)-36.40%

Year-to-Date Return6.36%

5-Day Price Return2.08%

EPS Normalized (Annual)$15.36

ROA (5Y Avg)13.54%

Net Profit Margin (Annual)25.89%

Month-to-Date Return16.01%

Cash Flow / Share (TTM)$32.63

EBITD / Share (Annual)$17.85

EPS Growth (3Y)9.58%

Operating Margin (Annual)28.63%

LT Debt / Equity (Annual)0.86x

P/CF (TTM)21.07x

ROI (5Y Avg)15.25%

P/E Excl Extra (TTM)23.82x

LT Debt / Equity (Quarterly)0.81x

EPS Basic Excl Extra (TTM)$12.69

P/TBV (Quarterly)4.77x

P/B Ratio (Annual)3.29x

Inventory Turnover (TTM)18.58x

Pretax Margin (TTM)21.93%

Book Value / Share (Annual)$94.89

Price vs S&P 500 (13W)24.57%

Net Margin Growth (5Y)-11.26%

Beta0.67x

P/FCF (Annual)16.60x

Revenue / Share (TTM)$66.94

ROE (TTM)13.56%

52-Week Low$1512.00

vGradeC

gGradeC

mGradeB

vgmGradeC

GMAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.35	$0.49	+41.78%(+$0.14)
Q1 2026	May 7, 2026	$0.19	$0.13	-29.74%(-$0.06)
Q4 2025	Feb 17, 2026	$0.37	$0.21	-44.55%(-$0.16)
Q3 2025	Nov 6, 2025	$0.45	$0.65	+42.31%(+$0.19)
Q2 2025	Aug 7, 2025	$0.34	$0.54	+61.37%(+$0.21)

GMAB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.78

3.84

3.88

3.92

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
GMABGenmab A/S ADS	C	C	B	$33.23
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.54

About Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company developing antibody therapeutics for cancer treatment, leveraging proprietary platforms including DuoBody, HexaBody, and DuoHexaBody. The company has a portfolio of approved products including Darzalex (the standard of care for multiple myeloma), Tepezza, Kesimpta, and others developed through strategic partnerships with major pharmaceutical companies. Genmab maintains a pipeline of candidates targeting additional oncologic indications.